ANNUAL REPORT
Idogen publishes prospectus in connection with the forthcoming rights issue - Nordic Life Science – the leading Nordic life science news service
Biostock intervjuar Idogens VD Anders Karlsson om kvartalsrapport Q4 samt företrädesemissionen - IPO.se
Idogen aktieägargrupp | Facebook
Idogen AB (publ) kommenterar handelsstoppet den 25 april 2019 - Idogen
Idogen's Historical Milestones - Idogen
Joakim Söderström - Idogen
Idogen AB (publ) Org nr
Idogen's Historical Milestones - Idogen
Investors Home
Idogen files patent application for new tolerogenic cell therapy
Annual Report
Idogen's IDO 8 granted orphan drug designation in the USA - Idogen
Idogen extends the project portfolio to projects in autoimmune diseases - Idogen
Idogen AB Interim report Idogen AB Interim report
niklas wallett - Idogen
Stories: EIC-funded company Idogen starts trading on Nasdaq First North Growth Market | EIC Community
40/20 – Information regarding the rights issue from Idogen AB
Idogen AB Interim report Idogen AB Interim report
Idogen's Historical Milestones - Idogen
PRESS RELEASE IDOGEN AB
Idogen's Historical Milestones - Idogen
Idogen's cell technology successfully advanced to large-scale production - Idogen
Annual Report
